ORGO Healthcare

Organogenesis Holdings Inc.

$0.83+10.45%

Price as of close on Nov 3, 2026 · Financials updated Oct 10, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Market cap: 107.4M USD
Enterprise value: 268.2M USD
Full-time employees: 854

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.27 vs a peer median of 0.63)bigger price swings (beta 1.27 vs peers 0.63)
About average: risk (debt, liquidity and share-price swings)risk

Ranks #1,037 of 1,157 healthcare companies (bottom 11%)

See how it ranks against its peers

Worth knowing

Profit growing, cash flow isn't. Profit +138% since 2022, operating cash flow −141%.
Organogenesis's reported profit rose 138% since 2022, but the cash its operations generate changed −141%. When profit and cash diverge like this, it's worth understanding why (for example, customers paying more slowly or gains that aren't cash).Organogenesis's reported profit rose 138% since 2022, but the cash its operations generate changed −141%. When profit and cash diverge like this, it's worth understanding why.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Organogenesis looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Organogenesis reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

26/ 100

Oct 5 26 → Nov 4 26

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-78.4%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-3.6%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield19.4%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingOutlier capped at sector 5th/95th percentile20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield138.0%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

30/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

12-month revenue fell 11.1%

Why

Weaker than most peers on:

▼ EPS growth
▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth0.0%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -0.69Sector median: 0.0584 · MAD: 0.0840

Revenue growth6.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.04Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

23/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Turned to a loss over the last 12 months
Operating margin fell 8.3 points to -7.8%

Why

Weaker than most peers on:

▼ ROIC
▼ ROA
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-7.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.22Sector median: 0.0706 · MAD: 0.1217

Return on assets-20.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.17Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-27.7%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.23Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin71.5%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-56.8%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.27

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.91Sector median: 0.6250 · MAD: 0.3380

Current ratio3.52×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.67Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.23×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score -0.05Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Organogenesis

Is Organogenesis getting weaker?: Its latest SEC filing (Aug 6, 2026) got weaker in some ways: turned to a loss over the last 12 months; operating margin fell 8.3 points to -7.8%. Its overall score is unchanged at 26/100 since Oct 28, 2026.
How is Organogenesis valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -78.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -78.4% vs peers 1.5% (weaker than 100% of peers).
Is Organogenesis growing?: More slowly than most of its peers. Growth scores 30/100 against 1,393 healthcare peers. 3-year revenue growth 0.0% vs a peer median of 5.8% (weaker than 71% of peers).3-year revenue growth 0.0% vs peers 5.8% (weaker than 71% of peers).
How profitable is Organogenesis?: Less profitable than most of its peers. Profitability scores 23/100 against 1,393 healthcare peers. Return on invested capital -27.7% vs a peer median of 4.7% (weaker than 82% of peers).Return on invested capital -27.7% vs peers 4.7% (weaker than 82% of peers).
How risky is Organogenesis?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 3.52× vs a peer median of 2.59× (stronger than 62% of peers).Current ratio 3.52× vs peers 2.59× (stronger than 62% of peers). Beta 1.27 vs a peer median of 0.63 (weaker than 82% of peers).Beta 1.27 vs peers 0.63 (weaker than 82% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Turned to a loss over the last 12 months
Operating margin fell 8.3 points to -7.8%
12-month revenue fell 11.1%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	514.7M USD	457.5M USD	−11.1%
Net income (12 months)	2.7M USD	−84.2M USD	turned negative
Operating margin	0.5%	-7.8%	−8.3 pts
Free cash flow (12 months)	17.1M USD	20.8M USD	+22.0%
Cash	91.4M USD	46.1M USD	−49.6%
Shares outstanding	128.7M	128.7M	0.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Drug Manufacturers - Specialty & Generic · 27 companies

Valuations in Drug Manufacturers - Specialty & Generic are within their usual range since Jun 2020.

45% of months since Jun 2020 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +8% vs the whole market, against a usual +36%.

Jun 2020Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	75.6%	76.7%	75.4%	76.0%	—	—
Operating margin	15.5%	4.9%	2.9%	-0.3%	7.9%	▲ 8.2 pts
Net margin	20.2%	3.4%	1.1%	0.2%	6.6%	▲ 6.4 pts
Return on assets (ROA)	21.3%	3.5%	1.1%	0.2%	6.2%	▲ 6.0 pts
Return on equity (ROE)	39.0%	5.8%	1.8%	0.3%	12.3%	▲ 12 pts
Free cash flow margin	6.6%	-2.0%	1.5%	0.9%	-4.3%	▼ 5.2 pts
Current ratio	2.74×	2.97×	2.80×	3.69×	3.62×	▼ 2.0%
Quick ratio	2.44×	2.64×	2.44×	3.35×	3.32×	▼ 0.9%
Debt to equity	0.31×	0.27×	0.24×	—	—	—
Interest coverage	9.98×	11.10×	5.72×	-0.83×	19.59×	▲ >999%

ORGO price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.27 vs a peer median of 0.63)bigger price swings (beta 1.27 vs peers 0.63)

About average: risk (debt, liquidity and share-price swings)risk

Ranks #1,037 of 1,157 healthcare companies (bottom 11%)

See how it ranks against its peers

Worth knowing

Profit growing, cash flow isn't. Profit +138% since 2022, operating cash flow −141%.

Organogenesis's reported profit rose 138% since 2022, but the cash its operations generate changed −141%. When profit and cash diverge like this, it's worth understanding why (for example, customers paying more slowly or gains that aren't cash).Organogenesis's reported profit rose 138% since 2022, but the cash its operations generate changed −141%. When profit and cash diverge like this, it's worth understanding why.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Organogenesis looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Organogenesis reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Organogenesis

Is Organogenesis getting weaker?

Its latest SEC filing (Aug 6, 2026) got weaker in some ways: turned to a loss over the last 12 months; operating margin fell 8.3 points to -7.8%. Its overall score is unchanged at 26/100 since Oct 28, 2026.

How is Organogenesis valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -78.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -78.4% vs peers 1.5% (weaker than 100% of peers).

Is Organogenesis growing?

More slowly than most of its peers. Growth scores 30/100 against 1,393 healthcare peers. 3-year revenue growth 0.0% vs a peer median of 5.8% (weaker than 71% of peers).3-year revenue growth 0.0% vs peers 5.8% (weaker than 71% of peers).

How profitable is Organogenesis?

Less profitable than most of its peers. Profitability scores 23/100 against 1,393 healthcare peers. Return on invested capital -27.7% vs a peer median of 4.7% (weaker than 82% of peers).Return on invested capital -27.7% vs peers 4.7% (weaker than 82% of peers).

How risky is Organogenesis?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 3.52× vs a peer median of 2.59× (stronger than 62% of peers).Current ratio 3.52× vs peers 2.59× (stronger than 62% of peers). Beta 1.27 vs a peer median of 0.63 (weaker than 82% of peers).Beta 1.27 vs peers 0.63 (weaker than 82% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

514.7M USD

457.5M USD

−11.1%

Net income (12 months)

2.7M USD

−84.2M USD

turned negative

Operating margin

0.5%

-7.8%

−8.3 pts

Free cash flow (12 months)

17.1M USD

20.8M USD

+22.0%

Cash

91.4M USD

46.1M USD

−49.6%

Shares outstanding

128.7M

128.7M

0.0%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

75.6%

76.7%

75.4%

76.0%

—

Operating margin

15.5%

4.9%

2.9%

-0.3%

7.9%

▲ 8.2 pts

Net margin

20.2%

3.4%

1.1%

0.2%

6.6%

▲ 6.4 pts

Return on assets (ROA)

21.3%

3.5%

1.1%

0.2%

6.2%

▲ 6.0 pts

Return on equity (ROE)

39.0%

5.8%

1.8%

0.3%

12.3%

▲ 12 pts

Free cash flow margin

6.6%

-2.0%

1.5%

0.9%

-4.3%

▼ 5.2 pts

Current ratio

2.74×

2.97×

2.80×

3.69×

3.62×

▼ 2.0%

Quick ratio

2.44×

2.64×

2.44×

3.35×

3.32×

▼ 0.9%

Debt to equity

0.31×

0.27×

0.24×

—

Interest coverage

9.98×

11.10×

5.72×

-0.83×

19.59×

▲ >999%